Health
FTC and seven states ask court to hold Martin Shkreli in contempt over ban
US regulators allege that the former pharmaceutical executive breached a 2022 lifetime industry ban by trading drug-company stocks and discussing the industry publicly; the reports reviewed by Vocemundi include no response from Shkreli.